5300 MEMORIAL DRIVE, HOUSTON, TX
Market cap: $5.2M (2/12/2026)
Price: $4.34
Shareholder votes
Investor Presentation
Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects
Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Other Events
News, Securities Holder Rights or Indentures, Material Contracts
Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Q3
Q2
Q1
Amended Annual Report
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRER14A
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload